The “Gold of Tech” Could Become Your Best Portfolio Insurance

0 | By Michael A. Robinson

Stocks have taken a big hit over the past month, and many investors are panicked. They’ve stopped buying and started unloading everything.

While such fear-based actions are understandable psychologically, they’re usually huge mistakes. If you manage your financial portfolio poorly right now, you’ll soon end up in the poor house.

That’s why I’ve set you all up with my five tools for beating choppy markets.

With these tactics at your side, you’ll avoid mistakes, turn turbulent markets to your advantage and sleep in peace.

And today I want to give you another option.

Millions of investors dedicate a portion of their portfolio to gold or some other precious metal as a hedge – as “insurance” – against trouble in other markets.

Now, some of these folks go overboard, and you probably know a “gold bug” or two. But at its base, this is a sound strategy, because precious metals generally aren’t effected by the ups and downs of the stock market.

This isn’t a “gold service,” however. Our interest is in tech.

So let’s spend today investigating what I think of as “the gold of tech.”

Not only can you use this investment as a hedge, but big banks, credit card companies and other financial players are beginning to eye the technology behind it as way to disrupt the $500 billion payments industry.

If that upheaval in payments transpires, this “safety” play could soar triple digits or more in the coming years.

Here’s why…

This 119-Year-Old “MedTech” Stock Is Primed for Triple-Digit Gains

0 | By Michael A. Robinson

If you paid attention to the headlines, you’d think now is a risky time to invest in healthcare.

First off, there’s the day-to-day turbulence we’ve been seeing for the past few months.

Plus, outrage about ObamaCare, high drug prices and rising medical bills means healthcare will remain a controversial – and volatile – sector in the short term.

But that’s just one side of the story.

Rapidly aging populations in North America, Europe and East Asia and ever more frequent and devastating disease outbreaks – like Ebola in 2014 and Zika right now – mean that healthcare spending is destined to escalate for years to come. For instance, global drug spending alone will soar 30% by 2020, to $1.4 trillion, according to IMS, making the life sciences as solid a long-term investment as you can find right now.

So today I want to introduce you to the one medical-tech firm that can get you through this temporary volatility. This company furnishes tools that are crucial for both doctors who treat aging populations here at home and the courageous medical professionals who battle epidemics around the world.

It’s a 119-year-old company that still generates double-digit earnings growth nearly every year.

It recently completed an acquisition that doubles the company’s addressable market to $16 billion.

And it’s set for triple-digit gains by 2021.

Take a look…